Showing papers by "Peter H. Schafer published in 2004"

Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases

Abstract: Methods of treating, preventing and/or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) and related syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Anti-proliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines

Abstract: 6618 Background: Phase I/II studies of CC-5013 (Revimid™) in MDS have shown erythropoietic and cytogenetic responses, especially among 5q- patients. The 5q deletion is a primary chromosomal change ...

Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system

Abstract: Methods of treating, preventing and/or managing central nervous system disorders, such as Parkinson disease, Alzheimer disease, mild cognitive impairment, Huntington disease, Amytophic Lateral Sclerosis, depression and defective long-term memory, and related syndromes are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases

Abstract: Methods of treating, preventing and/or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s Disease) and related syndromes are disclosed. Specific methods encompass the administration of thalidomide, or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage form, and kits suitable for use in methods of the invention are also disclosed.

A novel PDE4 inhibitory agent with endothelial cell specific activity.

Abstract: 2372 Anti-angiogenic agents selective for tumor vasculature have shown promise as anti-cancer therapies in clinical trials. We evaluated the potential anti-angiogenic role of a novel class of orally available small molecules known as selective cytokine inhibitory drugs or SelCids. One member of this class of compounds, designated CC10004, was investigated for its effects on endothelial cells, new blood vessel formation and wound healing. Cell proliferation was determined for human umbilical vein endothelial cells (HUVEC), and two human colon cancer cell lines (HT29 or KM12) using a WST-1 cell proliferation assay. Effects on vessel growth were measured using the rat aortic ring assay and the chicken chorioallantoic membrane assay (CAM). Wound healing was assessed in C57/Bl 6 mice following daily topical administration of the compound or control carrier using tensile strength assessment (Instron Tensometer) and by calculating time to wound closure. CC10004 demonstrated selective inhibitory effects on human umbilical vein endothelial cells (HUVEC) but not on HT29 or KM12, two human colon cancer cell lines, at doses from 73 to 7300 nM compared to controls (HUVEC 73 nM 61.4% decrease p

Immunomodulatory compounds for the treatment of central nervous system disorders

Abstract: Methods of treating, preventing and/or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s Disease) and related syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Composes immunomodulateurs pour traiter des troubles du systeme nerveux central

Abstract: L'invention concerne des methodes pour traiter, prevenir et/ou gerer des troubles du systeme nerveux central tels que la sclerose laterale amyotrophique (ALS ou maladie de Lou Gehrig) ainsi que des syndromes associes. Des methodes specifiques consistent a administrer un compose immunomodulateur de l'invention ou bien une substance pharmaceutiquement acceptable de celui-ci telle qu'un sel, un solvate, un hydrate, un stereoisomere, un clathrate ou un promedicament, seul ou combine a un deuxieme agent actif. La presente invention porte egalement sur des compositions pharmaceutiques, sur des posologies unitaires et sur des kits aptes a etre utilises dans les methodes de la presente invention.

Procedes d'utilisation et compositions comprenant des medicaments selectifs inhibiteurs de cytokine pour le traitement et la gestion de troubles du systeme nerveux central

Abstract: L'invention concerne des procedes de traitement, de prevention et/ou de gestion de troubles du systeme nerveux central, par exemple les maladies de Parkinson et d'Alzheimer, la deficience cognitive legere, la maladie de Huntington, la sclerose laterale amyotrophique, la depression et la deficience de memoire a long terme, et des syndromes connexes. L'invention concerne des procedes specifiques consistant notamment a administrer un medicament selectif inhibiteur de cytokine, ou un sel, un solvate, un hydrate, un stereoisomere, un clathrate, ou un promedicament pharmaceutiquement acceptable de celui-ci, seul ou combine a un second principe actif. Elle concerne egalement des compositions pharmaceutiques, des formes dosifiees unitaires, et des trousses appropriees pouvant etre utilisees dans ces procedes.